175 related articles for article (PubMed ID: 34247834)
21. Considerations in characterizing real-world data relevance and quality for regulatory purposes: A commentary.
Girman CJ; Ritchey ME; Zhou W; Dreyer NA
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):439-442. PubMed ID: 30515910
[No Abstract] [Full Text] [Related]
22. Rare cancer trial design: lessons from FDA approvals.
Gaddipati H; Liu K; Pariser A; Pazdur R
Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
[TBL] [Abstract][Full Text] [Related]
23. A clinical pharmacology-regulatory perspective on the approval of drugs for rare diseases.
Bashaw ED
Clin Pharmacol Ther; 2016 Oct; 100(4):327-9. PubMed ID: 27417549
[TBL] [Abstract][Full Text] [Related]
24. Drugs Against Rare Diseases: Are The Regulatory Standards Higher?
Gobburu J; Pastoor D
Clin Pharmacol Ther; 2016 Oct; 100(4):322-3. PubMed ID: 27326701
[TBL] [Abstract][Full Text] [Related]
25. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
Xu K; Coté TR
Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
[TBL] [Abstract][Full Text] [Related]
26. Rare-disease drugs to receive consideration on par with serious-disease drugs.
Thompson CA
Am J Health Syst Pharm; 2012 Nov; 69(22):1936-7. PubMed ID: 23135552
[No Abstract] [Full Text] [Related]
27. Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness.
Corrigan-Curay J; Sacks L; Woodcock J
JAMA; 2018 Sep; 320(9):867-868. PubMed ID: 30105359
[No Abstract] [Full Text] [Related]
28. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
29. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
Tambuyzer E
Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
[TBL] [Abstract][Full Text] [Related]
30. Regulatory perspectives on data monitoring.
O'Neill RT
Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099
[TBL] [Abstract][Full Text] [Related]
31. Accessing the accelerated approval pathway for rare disease therapeutics.
Kakkis ED; Kowalcyk S; Bronstein MG
Nat Biotechnol; 2016 Apr; 34(4):380-3. PubMed ID: 27054988
[No Abstract] [Full Text] [Related]
32. Rare Diseases: Addressing the Challenges in Diagnosis, Drug Approval, and Patient Access.
Copley-Merriman K
Value Health; 2018 May; 21(5):491-492. PubMed ID: 29753343
[No Abstract] [Full Text] [Related]
33. Regulating Rare Disease: Safely Facilitating Access to Orphan Drugs.
Bannister JB
Fordham Law Rev; 2018 Mar; 86(4):1889-921. PubMed ID: 29993206
[TBL] [Abstract][Full Text] [Related]
34. Accelerating access to treatments for rare diseases.
Dunoyer M
Nat Rev Drug Discov; 2011 Jun; 10(7):475-6. PubMed ID: 21701499
[TBL] [Abstract][Full Text] [Related]
35. Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
[TBL] [Abstract][Full Text] [Related]
36. Accelerated approval of oncology products: a decade of experience.
Dagher R; Johnson J; Williams G; Keegan P; Pazdur R
J Natl Cancer Inst; 2004 Oct; 96(20):1500-9. PubMed ID: 15494600
[TBL] [Abstract][Full Text] [Related]
37. Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders.
Mulberg AE; Bucci-Rechtweg C; Giuliano J; Jacoby D; Johnson FK; Liu Q; Marsden D; McGoohan S; Nelson R; Patel N; Romero K; Sinha V; Sitaraman S; Spaltro J; Kessler V
Orphanet J Rare Dis; 2019 Feb; 14(1):36. PubMed ID: 30736861
[TBL] [Abstract][Full Text] [Related]
38. Advocates call for long-term extension of the FDA's rare pediatric disease priority review program: Federal voucher program considered instrumental in shortening drug review, approval period.
Am J Med Genet A; 2017 Jan; 173(1):7-8. PubMed ID: 27991734
[No Abstract] [Full Text] [Related]
39. Challenges and Opportunities in Rare Disease Drug Development.
Smith BP
Clin Pharmacol Ther; 2016 Oct; 100(4):312-4. PubMed ID: 27612019
[TBL] [Abstract][Full Text] [Related]
40. Policy developments in regulatory approval.
Temple R
Stat Med; 2002 Oct; 21(19):2939-48. PubMed ID: 12325110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
